ICVTS Click here to goto Smart Canula website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Interact CardioVasc Thorac Surg 2006;5:317-321. doi:10.1510/icvts.2005.125856
© 2006 European Association of Cardio-Thoracic Surgery

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Christian Casali
Alessandro Stefani
Uliano Morandi
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casali, C.
Right arrow Articles by Morandi, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casali, C.
Right arrow Articles by Morandi, U.
Related Collections
Right arrow Lung - other
Right arrow Mediastinum

Institutional report - Pulmonary

Prognostic factors and survival after resection of lung metastases from epithelial tumours

Christian Casali, Alessandro Stefani, Erica Storelli and Uliano Morandi*

Division of Thoracic Surgery, Department of General Surgery and Surgical Specialities, Policlinico di Modena. University of Modena and Reggio Emilia, Largo del Pozzo 71, 41100, Modena, Italy

*Corresponding author. Tel.: +39-59-4222257; fax: +39-59-360159.

E-mail address: u.morandi{at}unimo.it (U. Morandi).

Lung metastasectomy is an accepted treatment for selected patients with pulmonary metastases. Resectability, disease-free interval and number of metastases are well characterised prognostic indicators after lung metastasectomy. Patients treated with lung metastasectomy for epithelial tumours were retrospectively reviewed. One hundred and forty-two patients were reviewed. The rate of mediastinal node metastases was 12%. Overall 5-year survival rate was 36% with a median survival time of 47 months. Recurrence rate after lung metastasectomy was 50%. Five-year disease-free survival was 26% with a median of 29 months. Mediastinal nodal status negatively affected survival at univariate analysis (5-years 32% for N+ and 40% for N–, P=0.013). Disease-free survival was significantly different according to nodal status: 5-year disease-free survival 17 and 28% for N+ and N–, respectively (P=0.053). Systemic recurrences were more frequent in patients with nodal involvement (P=0.058). Mediastinal nodal involvement resulted in a significant prognostic factor at multivariate analysis (N+: RRD=3.0; 95% CI 1.3–6.7). Patients with pulmonary metastases and nodal involvement had a poor prognosis and relapsed early after pulmonary metastasectomy. Nodal status should be considered in the selection of patients for lung metastasectomy.

Key Words: DFI: disease-free interval; DFS: disease-free survival; MST: median survival time; MLD: mediastinal lymph node dissection; SS: systematic sampling; PET: positron emission tomography; CT: computed tomography; RRD: relative risk of death







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 European Association for Cardio-thoracic Surgery